Purpose: Allergen immunotherapy (AIT) while usually safe, is not without risk. Both sublingual (SLIT) and subcutaneous immunotherapy (SCIT) have the potential for systemic reactions including anaphylaxis. Materials and Methods: A short survey was distributed to fellows of the American Academy of Otolaryngic Allergy (AAOA) (n = 553) in July of 2019 to determine current prescribing practices. Results: A total of 103/553 surveys were completed, giving a response rate of 18.6%. Prescribing patterns for SCIT showed 79.6% prescribed auto-injectable epinephrine (AIE) to all patients, 11.7% prescribed only to high risk patients, while 1.9% did not prescribe AIE at all. SLIT showed similar patterns with 71.8% prescribing AIE to all, 11.7% to high risk or letting patient choose, and 6.8% did not prescribe to anyone. Just under half of the physicians responded affirmatively to giving a written anaphylaxis plan to patients on immunotherapy. 48.5% physicians reported treating in-office anaphylaxis due to SCIT or skin testing in the past year, while 6% reported anaphylaxis due to SLIT. Conclusions: A majority of otolaryngic allergists are still prescribing AIE for both SCIT and SLIT. With the recent higher costs attributed to AIE as well as drug shortages, some physicians are risk-stratifying patients. While SCIT has a higher risk for treatment related systemic reactions, anaphylaxis does occur with SLIT, thus making it imperative to counsel patients on a clear anaphylaxis protocol in all forms of AIT.
References
[1]
Blomme, K., Tomassen, P., Lapeere, H., et al. (2013) Prevalence of Allergic Sensitization versus Allergic Rhinitis Symptoms in an Unselected Population. International Archives of Allergy and Immunology, 160, 200-207. https://doi.org/10.1159/000339853
[2]
Berger, W.E. (2004) Allergic Rhinitis in Children: Diagnosis and Management Strategies. Pediatric Drugs, 6, 233-250. https://doi.org/10.2165/00148581-200406040-00003
[3]
Nathan, R.A. (2007) The Burden of Allergic Rhinitis. Allergy & Asthma Proceedings, 28, 3-9. https://doi.org/10.2500/aap.2007.28.2934
[4]
Settipane, R.A. (2003) Rhinitis: A Dose of Epidemiological Reality. Allergy & Asthma Proceedings, 24, 147-154.
[5]
Mattos, J.L., Woodard, C.R. and Payne, S.C. (2011) Trends in Common Rhinologic Illnesses: Analysis of U.S. Healthcare Surveys 1995-2007. International Forum of Allergy & Rhinology, 1, 3-12. https://doi.org/10.1002/alr.20003
[6]
Bernstein, J.A. (2010) Allergic and Mixed Rhinitis: Epidemiology and Natural History. Allergy & Asthma Proceedings, 31, 365-369. https://doi.org/10.2500/aap.2010.31.3380
[7]
Meltzer, E.O. and Bukstein, D.A. (2011) The Economic Impact of Allergic Rhinitis and Current Guidelines for Treatment. Annals of Allergy, Asthma & Immunology, 106, S12-S16. https://doi.org/10.1016/j.anai.2010.10.014
[8]
Blaiss, M.S. (2010) Allergic Rhinitis: Direct and Indirect Costs. Allergy & Asthma Proceedings, 31, 375-380. https://doi.org/10.2500/aap.2010.31.3329
[9]
Pawankar, R., Canonica, G.W., Holgate, S., Lockey, R. and Blaiss, M. (2011) WAO White Book on Allergy. World Allergy Organization, Milwaukee.
[10]
Roberts, G., Pfaar, O., Akdis, C.A., et al. (2018) EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis. Allergy, 73, 765-798. https://doi.org/10.1111/all.13317
[11]
Pajno, G.B., Fernandez-Rivas, M., Arasi, S., et al. (2018) EAACI Guidelines on Allergen Immunotherapy: IgE-Mediated Food Allergy. Allergy, 73, 799-815. https://doi.org/10.1111/all.13319
[12]
Halken, S., Larenas-Linnemann, D., Roberts, G., et al. (2017) EAACI Guidelines on Allergen Immunotherapy: Prevention of Allergy. Pediatric Allergy and Immunology, 28, 728-745. https://doi.org/10.1111/pai.12807
[13]
Dhami, S., Nurmatov, U., Arasi, S., et al. (2017) Allergen Immunotherapy for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis. Allergy, 72, 1597-1631. https://doi.org/10.1111/all.13201
[14]
Nurmatov, U., Dhami, S., Arasi, S., et al. (2017) Allergen Immunotherapy for IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis. Allergy, 72, 1133-1147. https://doi.org/10.1111/all.13124
[15]
Kristiansen, M., Dhami, S., Netuveli, G., et al. (2017) Allergen Immunotherapy for the Prevention of Allergy: A Systematic Review and Meta-Analysis. Pediatric Allergy and Immunology, 28, 18-29. https://doi.org/10.1111/pai.12661
Calderon, M.A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A. and Durham, S. (2007) Allergen Injection Immunotherapy for Seasonal Allergic Rhinitis. Cochrane Database of Systematic Reviews, No. 1, CD001936. https://doi.org/10.1002/14651858.CD001936.pub2
[18]
Lin, S.Y., Erekosima, N., Kim, J.M., et al. (2013) Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: A Systematic Review. JAMA, 309, 1278-1288. https://doi.org/10.1001/jama.2013.2049
[19]
Erekosima, N., Suarez-Cuervo, C., Ramanathan, M., et al. (2014) Effectiveness of Subcutaneous Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: A Systematic Review. The Laryngoscope, 124, 616-627. https://doi.org/10.1002/lary.24295
[20]
Marogna, M., Tomassetti, D., Bernasconi, A., et al. (2008) Preventive Effects of Sublingual Immunotherapy in Childhood: An Open Randomized Controlled Study. Annals of Allergy, Asthma & Immunology, 101, 206-211. https://doi.org/10.1016/S1081-1206(10)60211-6
[21]
La Rosa, M., Ranno, C., André, C., Carat, F., Tosca, M.A. and Canonica, G.W. (1999) Double-Blind Placebo-Controlled Evaluation of Sublingual-Swallow Immunotherapy with Standardized Parietaria judaica Extract in Children with Allergic Rhinoconjunctivitis. The Journal of Allergy and Clinical Immunology, 104, 425-432. https://doi.org/10.1016/S0091-6749(99)70388-X
[22]
Wise, S.K., Lin, S.Y., Toskala, E., et al. (2018) International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. International Forum of Allergy & Rhinology, 8, 108-352. https://doi.org/10.1002/alr.22073
[23]
Cox, L.S., Larenas Linnemann, D., Nolte, H., Weldon, D., Finegold, I. and Nelson, H.S. (2006) Sublingual Immunotherapy: A Comprehensive Review. The Journal of Allergy and Clinical Immunology, 117, 1021-1035. https://doi.org/10.1016/j.jaci.2006.02.040
[24]
Epstein, T.G., Calabria, C., Cox, L.S. and Dreborg, S. (2017) Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States. The Journal of Allergy and Clinical Immunology: In Practice, 5, 34-40.e2. https://doi.org/10.1016/j.jaip.2016.09.017
[25]
Epstein, T.G., Liss, G.M., Murphy-Berendts, K. and Bernstein, D.I. (2016) Risk Factors for Fatal and Nonfatal Reactions to Subcutaneous Immunotherapy: National Surveillance Study on Allergen Immunotherapy (2008-2013). Annals of Allergy, Asthma & Immunology, 116, 354-359.e2. https://doi.org/10.1016/j.anai.2016.02.001
[26]
Reid, M.J., Lockey, R.F., Turkeltaub, P.C. and Platts-Mills, T.A. (1993) Survey of Fatalities from Skin Testing and Immunotherapy 1985-1989. The Journal of Allergy and Clinical Immunology, 92, 6-15. https://doi.org/10.1016/0091-6749(93)90030-J
[27]
Bernstein, D.I., Wanner, M., Borish, L., Liss, G.M., Immunotherapy Committee and American Academy of Allergy, Asthma and Immunology (2004) Twelve-Year Survey of Fatal Reactions to Allergen Injections and Skin Testing: 1990-2001. The Journal of Allergy and Clinical Immunology, 113, 1129-1136. https://doi.org/10.1016/j.jaci.2004.02.006
[28]
Patel, A., Fisher, K., Fornadley, J., Wilson, K. and Iudenkova, O. (2015) American Academy of Otolaryngic Allergy Clinical Care Statements. http://www.aaoallergy.org/wp-content/uploads/2017/05/2015.Clinical-Care-Statements-Bro.web_.pdf
[29]
Cox, L., Nelson, H., Lockey, R., et al. (2011) Allergen Immunotherapy: A Practice Parameter Third Update. The Journal of Allergy and Clinical Immunology, 127, S1-S55. https://doi.org/10.1016/j.jaci.2010.09.034
[30]
Gupta, P., Gerrish, P.K., Silverman, B. and Schneider, A. (2012) Current Practices among Allergists on Writing Self-Injectable Epinephrine Prescriptions for Immunotherapy Patients. The Journal of Allergy and Clinical Immunology, 129, 571-572, 572.e1-2. https://doi.org/10.1016/j.jaci.2011.09.033
[31]
Bousquet, J.J., Schünemann, H.J., Togias, A., et al. (2019) Next-Generation ARIA Care Pathways for Rhinitis and Asthma: A Model for Multimorbid Chronic Diseases. Clinical and Translational Allergy, 9, 44. https://doi.org/10.1186/s13601-019-0279-2
[32]
Sampson, H.A., Muñoz-Furlong, A., Campbell, R.L., et al. (2006) Second Symposium on the Definition and Management of Anaphylaxis: Summary Report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. The Journal of Allergy and Clinical Immunology, 117, 391-397. https://doi.org/10.1016/j.jaci.2005.12.1303
[33]
Lieberman, P., Nicklas, R.A., Oppenheimer, J., et al. (2010) The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update. The Journal of Allergy and Clinical Immunology, 126, 477-480.e1-42. https://doi.org/10.1016/j.jaci.2010.06.022
[34]
Amin, H.S., Liss, G.M. and Bernstein, D.I. (2006) Evaluation of Near-Fatal Reactions to Allergen Immunotherapy Injections. The Journal of Allergy and Clinical Immunology, 117, 169-175. https://doi.org/10.1016/j.jaci.2005.10.010
[35]
Sun, D., Cafone, J., Shaker, M. and Greenhawt, M. (2019) The Cost-Effectiveness of Requiring Universal vs Contextual Self-Injectable Epinephrine Autoinjector for Allergen Immunotherapy. Annals of Allergy, Asthma & Immunology, 123, 582-589. https://doi.org/10.1016/j.anai.2019.09.009
[36]
Simons, F.E.R., Ardusso, L.R.F., Dimov, V., et al. (2013) World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. International Archives of Allergy and Immunology, 162, 193-204. https://doi.org/10.1159/000354543
[37]
Roy, S.R., Sigmon, J.R., Olivier, J., Moffitt, J.E., Brown, D.A. and Marshall, G.D. (2007) Increased Frequency of Large Local Reactions among Systemic Reactors during Subcutaneous Allergen Immunotherapy. Annals of Allergy, Asthma & Immunology, 99, 82-86. https://doi.org/10.1016/S1081-1206(10)60626-6
[38]
Kokosky, G. (2019) Newly Approved Generic Version of EpiPen Is Not Cheaper than Available Option: Teva’s Epinephrine Injection May Not Undercut Mylan’s on Price, But It Could Help in Addressing Shortages. Pharmacy Times, 85, 44.
